This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Morgan & Morgan Announces The Investigation Of Chemed Corporation (NYSE: CHE)

NEW YORK, May 8, 2013 /PRNewswire/ -- Morgan & Morgan announces that it is investigating possible securities law violations by Chemed Corporation ("Chemed" or the "Company") (NYSE: CHE) following the U.S. Department of Justice's ("DOJ") filing of a lawsuit alleging that Chemed's Vitas Hospice units ("Vitas") knowingly overbilled the Government's Medicare program.   

If you purchased Chemed and want more information about the Chemed securities fraud class action, please contact George Pressly, Esq. at 1 (800) 631-6234 or email George at

Specifically, the DOJ complaint alleges that Chemed and Vitas (collective, the "companies") knowingly submitted, or caused the submission of, false claims to Medicare for crisis care services that were either not necessary, not actually provided, or not performed in accordance with Medicare requirements.   According to the DOJ's complaint, the companies allegedly used aggressive marketing tactics and pressured staff to increase the numbers of crisis care claims submitted to Medicare without regard to whether the services were appropriate or were actually being provided.  In addition, the DOJ alleges that the companies knowingly submitted, or caused the submission, of false claims for hospice care for patients who were not terminally ill.    

As a result of the conduct alleged in the DOJ complaint, the government contends that the companies violated the False Claims Act and misspent tens of millions of taxpayer dollars from the Medicare program.

Morgan & Morgan's investigation is focused on the time period between May 2, 2008 and May 2, 2013 to determine primarily whether Chemed or its officers and directors violated the federal securities laws by artificially and materially inflating its financial results. 

Morgan & Morgan

Morgan & Morgan is one of the nation's largest 200 law firms. In addition to securities fraud, the firm also practices in the areas of antitrust, consumer class actions, personal injury, consumer protection, overtime, and product liability.  All of the Firm's legal endeavors are rooted in its core mission: provide investor and consumer protection and always fight "for the people." 

Attorney advertising. Prior results do not guarantee a similar outcome.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs